Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
Nexalin Technology (Nasdaq: NXL) will host a live investor webinar on June 3, 2025, at 4:15 p.m. ET. CEO Mark White will present the company's proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology for mental healthcare and provide updates on their Gen-3 HALO™ Clarity headset and Virtual Clinic model for at-home treatment. The presentation will highlight clinical collaborations with institutions like UC San Diego, international regulatory approvals, and U.S. expansion plans in the $537 billion mental health market. The webinar will include discussion of Nexalin's patented technology, AI-driven patient monitoring, and global expansion strategy, followed by a Q&A session.
Nexalin Technology (Nasdaq: NXL) terrà un webinar live per investitori il 3 giugno 2025 alle 16:15 ET. L'amministratore delegato Mark White presenterà la tecnologia proprietaria dell'azienda, la Deep Intracranial Frequency Stimulation (DIFS™) per la salute mentale, e fornirà aggiornamenti sul Gen-3 HALO™ Clarity headset e sul modello di Clinica Virtuale per il trattamento domiciliare. La presentazione metterà in luce le collaborazioni cliniche con istituzioni come UC San Diego, le approvazioni regolatorie internazionali e i piani di espansione negli Stati Uniti nel mercato della salute mentale da 537 miliardi di dollari. Il webinar includerà una discussione sulla tecnologia brevettata di Nexalin, il monitoraggio dei pazienti basato su intelligenza artificiale e la strategia di espansione globale, seguita da una sessione di domande e risposte.
Nexalin Technology (Nasdaq: NXL) realizará un seminario web en vivo para inversores el 3 de junio de 2025 a las 4:15 p.m. ET. El CEO Mark White presentará la tecnología propietaria de la compañía, la Estimulación de Frecuencia Intracraneal Profunda (DIFS™) para el cuidado de la salud mental, y ofrecerá actualizaciones sobre el Gen-3 HALO™ Clarity headset y el modelo de Clínica Virtual para tratamiento en casa. La presentación destacará colaboraciones clínicas con instituciones como UC San Diego, aprobaciones regulatorias internacionales y planes de expansión en EE.UU. en el mercado de salud mental valorado en 537 mil millones de dólares. El seminario incluirá una discusión sobre la tecnología patentada de Nexalin, el monitoreo de pacientes impulsado por IA y la estrategia de expansión global, seguida de una sesión de preguntas y respuestas.
Nexalin Technology (나스닥: NXL)는 2025년 6월 3일 오후 4시 15분(동부시간)에 투자자 대상 라이브 웨비나를 개최합니다. CEO Mark White는 정신 건강 관리를 위한 회사의 독자적인 심부 두개 내 주파수 자극(Deep Intracranial Frequency Stimulation, DIFS™) 기술을 소개하고, Gen-3 HALO™ Clarity 헤드셋 및 가정 치료를 위한 가상 클리닉 모델에 대한 최신 정보를 제공합니다. 발표에서는 UC San Diego와 같은 기관과의 임상 협력, 국제 규제 승인, 5370억 달러 규모의 정신 건강 시장에서 미국 내 확장 계획이 강조될 예정입니다. 웨비나에는 Nexalin의 특허 기술, AI 기반 환자 모니터링, 글로벌 확장 전략에 대한 논의가 포함되며, 질의응답 시간도 마련됩니다.
Nexalin Technology (Nasdaq : NXL) organisera un webinaire en direct pour les investisseurs le 3 juin 2025 à 16h15 ET. Le PDG Mark White présentera la technologie propriétaire de l'entreprise, la Stimulation Fréquentielle Intracrânienne Profonde (DIFS™) pour les soins de santé mentale, et fournira des mises à jour sur le casque Gen-3 HALO™ Clarity ainsi que sur le modèle de Clinique Virtuelle pour le traitement à domicile. La présentation mettra en avant les collaborations cliniques avec des institutions comme l'UC San Diego, les approbations réglementaires internationales, ainsi que les plans d'expansion aux États-Unis sur le marché de la santé mentale, évalué à 537 milliards de dollars. Le webinaire comprendra une discussion sur la technologie brevetée de Nexalin, la surveillance des patients basée sur l'IA et la stratégie d'expansion mondiale, suivie d'une session de questions-réponses.
Nexalin Technology (Nasdaq: NXL) wird am 3. Juni 2025 um 16:15 Uhr ET ein Live-Webinar für Investoren veranstalten. CEO Mark White wird die firmeneigene Deep Intracranial Frequency Stimulation (DIFS™)-Technologie für die psychische Gesundheitsversorgung vorstellen und Updates zum Gen-3 HALO™ Clarity Headset sowie zum Virtual Clinic-Modell für die Behandlung zu Hause geben. Die Präsentation wird klinische Kooperationen mit Institutionen wie der UC San Diego, internationale Zulassungen und Expansionspläne in den USA im 537 Milliarden Dollar schweren Markt für psychische Gesundheit hervorheben. Das Webinar umfasst eine Diskussion über Nexalins patentierte Technologie, KI-gesteuertes Patientenmonitoring und die globale Expansionsstrategie, gefolgt von einer Fragerunde.
- None.
- None.
HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.m. ET.
Attendees will gain an inside look at Nexalin’s game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. CEO Mark White will detail the Company’s growing body of clinical evidence, including collaborations with leading institutions like UC San Diego, and share updates on the Gen-3 HALO™ Clarity headset and Virtual Clinic model—designed for scalable, at-home treatment. With regulatory approvals secured internationally and U.S. expansion underway, Nexalin is positioned at the forefront of a
To register for the free webinar, please visit: https://www.redchip.com/webinar/NXL/88521574435.
Questions can be pre-submitted to NXL@redchip.com or online during the live event.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
NXL@redchip.com
FAQ
When is Nexalin Technology (NXL) hosting its investor webinar?
What will be discussed in Nexalin's (NXL) June 2025 investor webinar?
How can investors register for Nexalin's (NXL) June 2025 webinar?
What is the market size for mental health that Nexalin (NXL) is targeting?
